Blood plasma is an indispensable resource in the production of life-saving medicines. It is in high demand on global markets. To make more efficient use of this valuable commodity, Biotest AG developed a new large-scale plant for plasma fractionation, with which it is possible to obtain five instead of the previous three products from a liter of plasma. Standardized components from Festo simplify installation and maintenance.
Blood plasma contains more than 120 valuable proteins. These include clotting factors, blood substitutes and immunoglobulins, which can strengthen the weakened immune system of patients after an organ transplant, for example. In order to be able to make the best possible use of this valuable raw material, companies like Biotest AG are investing in research and innovative manufacturing methods. The investment is paying off, as the number of medical products that can be obtained from a liter of blood plasma has increased from three to five. It is also contributing to a lasting increase in productivity, as more than 50 per cent of the production costs are incurred in buying plasma. More efficient methods ensure optimum processing of the various products obtained from blood plasma. In Biotest's new production plant, 6000 valves and 250 standardized control cabinets simplify the construction and subsequent maintenance of the plants as well as delivering a long-term reduction in maintenance costs.
Standardization in the construction of the new Biotest plant for blood plasma fractionation offers benefits for both the company and the plant engineers. Plant engineers can purchase predefined components quickly and easily and get access to favorable terms thanks to a defined component pool, while for Biotest the overall cost for spare parts supply is reduced. Other benefits include a reduced training requirement for maintenance and service staff, shorter downtimes as well as reduced repair workload in the event of a fault. It also means lower documentation and supply management costs.
Simplifies maintenance: the control cabinets from Festo were already defined as the standard in the planning phase.
"When it came to the construction of the new building with the modern large-scale plant for blood plasma fractionation, there were two main aspects to consider," explains Matthias Mahle, Head of Technical Project Management BNL at Biotest. "The first was expansion of capacity beyond the performance limits of the existing plants, and the other was efficiency. As a pharmaceutical company working in blood plasma processing, we are competing in a globally consolidating market. We are strengthening our market position by obtaining more products from the same amount of plasma," says Mahle. In the new plant, Biotest will be able to manufacture a greater number of products as well as increase their yield and purity. "With the existing systems, some of which date back to 1995, we were able to obtain three different products from the plasma. The new plants will be able to manufacture up to six products," emphasizes Mahle. "A high level of efficiency in production is essential, as the raw material ‒ blood plasma ‒ accounts for more than 50 per cent of the production costs." Whereas the capacity limit used to be 800,000 liters, the new plant will be able to fractionate up to 1.4 million liters of blood plasma.